Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.

Details

Ressource 1Download: serval:BIB_E6BF21E87E7A.P001 (450.18 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_E6BF21E87E7A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
Journal
Clinical Infectious Diseases
Author(s)
Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E., Schmid P., Bae H.G., Litzba N., Staub T., Hatz C., Furrer H.
Working group(s)
Swiss HIV Cohort Study
Contributor(s)
Battegay M., Bernasconi E., Böni J., Bucher H., Bürgisser P., Cattacin S., Cavassini M., Dubs R., Egger M., Elzi L., Erb P., Fischer M., Flepp M., Fontana A., Francioli P., Furrer H., Gorgievski M., Günthard H., Hirsch H., Hirschel B., Hösli I., Kahlert Ch., Kaiser L., Karrer U., Kind C., Klimkait T., Ledergerber B., Martinetti G., Martinez B., Müller N., Nadal D., Opravil M., Paccaud F., Pantaleo G., Rickenbach M., Rudin C., Schmid P., Schultze D., Schüpbach J., Speck R., Taffé P., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Publication state
Published
Issued date
03/2009
Peer-reviewed
Oui
Volume
48
Number
5
Pages
659-666
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
BACKGROUND: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)-infected patients, and adequate immunogenicity and safety are of concern in this population.
METHODS: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:>or=10 were defined as reactive, and those of 1:<10 were defined as nonreactive, which was considered to be nonprotective. The results were compared with data for HIV-uninfected individuals. Serious adverse events were defined as hospitalization or death within 6 weeks after receipt of 17DV.
RESULTS: At the time of 17DV administration, the median CD4 cell count was 537 cells/mm(3) (range, 11-1730 cells/mm(3)), and the HIV RNA level was undetectable in 41 of 102 HIV-infected patients. During the first year after vaccination, fewer HIV-infected patients (65 [83%] of 78; P = .01) than HIV-uninfected patients revealed reactive NTs, and their NTs were significantly lower (P < .001) than in HIV-uninfected individuals. Eleven patients with initially reactive NTs lost these reactive NTs <or= 5 years after vaccination. Higher NTs during the first year after vaccination were associated with undetectable HIV RNA levels, increasing CD4 cell count, and female sex. We found no serious adverse events after 17DV administration among HIV-infected patients.
CONCLUSION: Compared with HIV-uninfected individuals, HIV-infected patients respond to 17DV with lower reactive NTs, more often demonstrate nonprotective NTs, and may experience a more rapid decline in NTs during follow-up. Vaccination with 17DV appears to be safe in HIV-infected individuals who have high CD4 cell counts, although rate of serious adverse events of up to 3% cannot be excluded.
Keywords
Adult, Antibodies, Viral/blood, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections/immunology, Humans, Male, Neutralization Tests, RNA, Viral/blood, Switzerland, Viral Load, Viral Plaque Assay, Yellow Fever/immunology, Yellow Fever/prevention & control, Yellow Fever Vaccine/adverse effects, Yellow Fever Vaccine/immunology
Pubmed
Web of science
Open Access
Yes
Create date
05/03/2009 15:58
Last modification date
25/09/2019 6:11
Usage data